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Cardiac assessment of patients with late
stage Duchenne muscular dystrophy
Background. Duchenne muscular dystrophy (DMD)
patients used to die mainly from pulmonary
problems. However, as advances in respiratory care
increase life expectancy, mortality due to cardio-
myopathy rises. Echocardiography remains the
standard diagnostic modality for cardiomyopathy
in DMD patients, but is hampered by scoliosis and
poor echocardiographic acoustic windows in adult
DMD patients. Multigated cardiac radionuclide
ventriculography (MUGA) does not suffer from
these limitations. N-terminal proBNP (NT-
proBNP) has shown to be a diagnostic factor for
heart failure. We present our initial experience with
plasma NT-proBNP measurement in the routine
screening and diagnosis of cardiomyopathy in adult
mechanically ventilated DMD patients. 
Methods. Retrospective study, 13 patients. Echo-
cardiography classified left ventricular (LV)
function as preserved or depressed. NT-proBNP
was determined using immunoassay. LV ejection
fraction (LVEF) was determined using MUGA. 
Results. Median (range) NT-proBNP was 73 (25
to 463) ng/l. Six patients had an NT-proBNP
>125 ng/l. Seven patients showed an LVEF <45%
on MUGA. DMD patients with depressed LV
function (n=4) as assessed by echocardiography
had significantly higher median NT-proBNP than
those (n=9) with preserved LV function: 346 (266
to 463) ng/l versus 69 (25 to 257) ng/l (p=0.003).
NT-proBNP significantly correlated with de-
pressed LV function on echocardiogram and with
LVEF determined by MUGA.
Conclusion. Although image quality of MUGA is
superior to echocardiography, the combination of
echocardiography and NT-proBNP achieves similar
results in the evaluation of left ventricular function
and is less time consuming and burdensome for
our patients. We advise to add NT-proBNP to
echocardiography in the routine cardiac assessment
of DMD patients. (Neth Heart J 2009;17:232-7.)
Keywords: natriuretic peptides, echocardiography,
multigated radionuclide ventriculography, cardio-
myopathy, home mechanical ventilation, Duchenne
muscular dystrophy
Duchenne muscular dystrophy (DMD) is an X-linked recessive muscular dystrophy caused by
mutations in the dystrophin gene. The annual
incidence is one per 3000 live male births. DMD
patients used to die in their late teens or early twenties
mainly from pulmonary problems. However, as
advances in respiratory care increase life expectancy,
morbidity and mortality due to cardiomyopathy rises.
Preclinical cardiac involvement has been found in 25%
of patients under 6 years of age, increasing to 60%
between the ages of 6 and 10 years and then declining
in incidence with age. Clinically apparent cardio-
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myopathy is first evident after 10 years of age and
increases in incidence with age, being present in all
patients over 18 years.1,2 Progressive cardiomyopathy
is a common cause of death in Duchenne muscular
dystrophy, presumably secondary to fibrosis of the
myocardium. The posterobasal and left lateral free wall
of the left ventricle are initial sites of myocardial fibrosis
pathologically.3,4 Currently, 10 to 50% of DMD
patients die of heart failure.5,6
A diagnosis of cardiomyopathy is not easily made
in these patients. Interpretation of patient complaints,
such as fatigue and decreased exercise tolerance, can be
very difficult. Immobility, deformities, and pulmonary
failure additionally obscure the clinical and radiographic
signs and symptoms of heart failure. Because of the
elusive nature of the disease additional tools for cardiac
evaluation are often used in clinical work-up.
Echocardiography remains the standard diagnostic
modality for cardiomyopathy in DMD patients and
consensus meetings advise annual echocardiograms
after the age of 10.1 However, scoliosis and poor echo-
cardiographic acoustic windows in adult DMD patients
hamper accurate assessment. Multigated cardiac radio-
nuclide ventriculography (MUGA) is not affected by
these problems and has been found to be sensitive in
detecting subclinical DMD cardiomyopathy.7 How-
ever, MUGA is not easy to perform in DMD patients
and, moreover, it is associated with radiation exposure,
which is even more relevant in case of repeated
investigations.
Taken together, there is a need for an easier
approach to gathering information about cardiac
function. The natriuretic peptides, brain natriuretic
peptide (BNP) and N-terminal proBNP (NT-
proBNP), are useful as diagnostic factors for heart
failure in patients presenting to an emergency depart-
ment with acute dyspnoea and may provide prognostic
information in patients with congestive heart failure.8,9
In a group of DMD patients that were not on mech-
anical ventilation, plasma levels of BNP were associated
with systolic dysfunction.10
The goal of this retrospective study is to present
our initial experience with plasma NT-proBNP
measurement in the routine screening and diagnosis
of cardiomyopathy in home mechanically ventilated




Between April 2005 and March 2006 all DMD patients
attending the multidisciplinary outpatient clinic of our
tertiary care hospital, who had a routine physical
examination and cardiac work-ups including echo-
cardiography, MUGA scanning and NT-proBNP
assessment in one day, were included in this study
report. The patients were older than 16 years of age
and were on mechanical ventilatory support. Informed
consent for the procedures was given by each patient.
We obtained clinical follow-up information through
chart review for all patients. 
Measurements
Echocardiography was performed by skilled on duty
technicians using a General Electric VIVID 7 system
with a 2.5 mHz probe and consisted of two-
dimensional views in the parasternal long axis and short
axis, and the apical view, according to standard
procedures and definitions.11 LV systolic function was
classified qualitatively as preserved or depressed. Plasma
NT-proBNP was determined using the commercially
available Elecsys proBNP immunoassay by Roche. The
FDA approved cut-off value of 125 ng/l for NT-
proBNP was used to define systolic dysfunction.
MUGAs were standardised and performed in the
left anterior oblique projection after the in vivo label-
ling of red blood cells with 500 MBq of 99mTc-
pertechnetate to determine left ventricular ejection
fraction (LVEF). A single-detector gamma camera
(Orbiter, Siemens Medical Systems, Chicago, Illinois,
USA) with a low energy, all purpose collimator was
used. The camera head was positioned in the best septal
left anterior oblique projection, typically with a caudal
tilt of 5 to 10°. R-wave triggering was performed in a
20% beat acceptance window with 2/3 forward and
1/3 backward framing per cardiac cycle, for 20 frames
per R-R interval for a total of six minutes. Data were
acquired using 64×64 matrices in a 15% energy window
centred on the 140 keV photopeak. Processing was
performed on dedicated available computers (ICON,
Siemens Medical Systems, Chicago, Illinois, USA).
For each of the 20 frames a region of interest (ROI)
was automatically drawn around the left ventricle using
a validated, fully automated, operator independent,
contour detection algorithm. Frames were automatical-
ly corrected for background activity. Background
activity ROIs were generated automatically. All LVEF
values were generated without decimals and are highly
reproducible.12 The cut-off value of LVEF <45% was
considered to indicate a significantly depressed systolic
LV function.12 All measurements were carried out in
one day.
Statistical analysis
With SPSS version 14 we used Spearmann correlation
for continuous variables and Mann Whitney U test
when appropriate to compare groups. The results are
given as median (range) unless otherwise specified.
P<0.05 was considered statistically significant. 
Results
Patient characteristics
A total of 28 DMD patients attended our multi-
disciplinary outpatient clinic in this period. All were
wheelchair dependent males with either non-invasive
(via nose or facial mask) or invasive (via tracheostomy)
assisted ventilation. Echocardiography, MUGA and
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measurement of NT-proBNP was performed for
routine yearly cardiac assessment. We chose the patients
who underwent all three investigations and all in one
day in order to make a reliable comparison. Thirteen
patients met these inclusion criteria; nine patients did
not receive all three investigations in one day and six
patients did not consent to all three investigations,
because they expected that the investigations would
be too burdensome. 
Patient demographics and results of clinical assess-
ment of the 13 included patients are summarised in
table 1. Seven patients were taking cardiac medication:
angiotensin-converting enzyme (ACE) inhibitor (6
patients) and β-blockers (2 patients). One patient had
clear clinical signs and symptoms compatible with heart
failure, as judged by the attending cardiologist. 
Plasma NT-proBNP 
The median NT-proBNP of 13 patients was 73 ng/l
(range 25-463). Seven patients showed a normal NT-
proBNP level (<125 ng/l). No statistically significant
relationship could be detected between the NT-
proBNP level and age, cardiac medication, type of
ventilatory support, length of time since ventilator
dependence or daily assisted ventilation requirement.
MUGA - NT-proBNP 
Figure 1 shows NT-proBNP levels of patients with
preserved LV function (MUGA LVEF >45%) versus
those with depressed LV function (MUGA LVEF
<45%) (p=0.015 between groups). Mean (SD) LVEF
in 13 patients was 45 (11). Seven patients showed an
LVEF <45% and they had a higher median (range) of
NT-proBNP 266 (30 to 463) ng/l than those patients
with LVEF >45%: 58 (25 to 73) ng/l (p=0.014).
There was an inverse relationship between NT-
proBNP and LVEF (r=-0.64, p=0.018). 
Echocardiography - NT-proBNP 
Poor acoustic windows were mentioned in all patients.
Due to the poor image quality no LVEF percentage
was given in any of the patients. Preserved left
ventricular (LV) function was found in nine patients
and depressed LV function in four patients. DMD
patients with depressed LV function (n=4) as assessed
by echocardiography had higher median (range) NT-
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Table 1. Baseline characteristics of study population.
Patient characteristic (n=13) Patients
Age, median (range) 19 (16-36)
Wheelchair bound, n (%) 13 (100%)
VC, litres (n=8), median (range) 0.89 (0.36-2.5)
sO2% (n=10), median (range) 96 (90-98)
Minute volume, l/min (n=13), median (range) 9.9 (7.0-14.7)
NIPPV, n (%) 8 (61.5)
Invasive ventilation, n (%) 5 (38.5)
Night-time ventilation, n (%) 9 (69.2)
24-hour ventilation, n (%) 4 (30.8)
Duration of ventilation, years, (n=13) median (range) 4 (0.5-13.5)
Heart rate, beats/min (n=13), median (range) 88 (64-124)
Cardiac medication, (n=13) n (%)* 7 (53.8)
Clinical heart failure, n (%) 1 (7.7)  
FEV1 =forced expiratory volume in one second, VC=vital capacity, SpO2=saturation of peripheral oxygen, NIPPV=non-invasive positive pressure ventilation, 
*ACE-inhibitor (6), β-blocker (2).








Figure 1. Left ventricular ejection fraction (%) measured by multi-
gated cardiac radionuclide ventriculography (MUGA) grouped
by preserved and depressed function and NT-proBNP levels in
individual patients. 
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proBNP than those (n=9) with preserved LV function:
346(266 to 463) ng/l vs. 69(25 to 257) ng/l
(p=0.003). 
Echocardiography combined with NT-proBNP versus
MUGA
Figure 2 shows the results of LV function assessment
by echocardiography and plasma NT-proBNP com-
pared with LVEF determined by MUGA. In all but one
patient, the combined results of NT-proBNP and
echocardiography are similar to those with LVEF
determined by MUGA: all six patients with plasma
NT-proBNP >125 ng/l and/or depressed LV function
on echocardiography showed LVEF <45% on MUGA.
Six out of seven patients with low NT-proBNP and
preserved function on echocardiography showed
LVEF >45% on MUGA. In one patient NT-proBNP
was 30 ng/l and echocardiography showed preserved
LV function, while LVEF on MUGA was 37%. Echo-
cardiography results from previous years showed
depressed left ventricular function. This 36-year-old
patient did not receive cardiac medication and had
been on long-term ventilatory support since 1992. 
Discussion 
Decline in cardiac function in DMD occurs early in
life. Detecting cardiomyopathy can be a particularly
frustrating problem to patients and physicians due to
the elusive and non-specific symptoms associated with
the non-ambulatory state.2 In our population only one
patient had overt clinical features of heart failure. In this
retrospective study we evaluated the relationship
between echocardiography, MUGA and NT-proBNP
levels in DMD patients that were on home mechanical
ventilated support. Combining echocardiography with
NT-proBNP values in the assessment of left ventricular
function, we found similar results compared with
LVEF determined by MUGA: all patients with plasma
NT-proBNP >125 ng/l and depressed LV function
on echocardiography showed LVEF <45% on MUGA.
In all but one patient low NT-proBNP and preserved
function on echocardiography was associated with
LVEF >45% on MUGA. In this patient NT-proBNP
was 30 ng/l and echocardiography showed preserved
LV function, while LVEF on MUGA was 37%.
We realise this is a small sample; nevertheless, there
is no other literature comparing echocardiography,
NT-proBNP and MUGA scan in an adult ventilated
Duchenne patient group. Further studies are needed
to confirm our conclusion.
In view of the prevalence of LV abnormalities,
plasma NT-proBNP levels were relatively low in our
patients. This is consistent with others that postulated
it to be due to patients’ physical inactivity limiting
cardiac workload and therefore ventricular stress.10,13 An
alternative hypothesis is that the heart of DMD patients
is unable to make sufficient natriuretic peptides due to
the presence of cardiac fibrosis.2,10 However, we con-
sider this unlikely as we have seen high levels in cases
of end-stage DMD (personal observation). Several
studies similarly found high plasma BNP levels in
deceased DMD patients.10,14 Another suggestion, as
supported by Ishikawa, is that low levels are a con-
sequence of cardioprotective medication.14 Our data did
not clearly demonstrate a relationship between the use
of cardiac medication and NT-proBNP levels. An
alternative explanation would be obesity, which is a
common finding in Duchenne patients. Unfortunately,
weight was not recorded in our patients but we do
recognise obesity as a potential cause of low natriuretic
peptides, as has been seen in other patient groups.15
Studies using cardiac magnetic resonance tech-
niques involving delayed enhancement techniques
identify early regional myocardial fibrosis correlating
with LV dysfunction.3,4 As found in earlier studies,10
there was relative sparing of the right ventricle. Further-
more, as LV dysfunction is also the main predictor of
mortality in DMD patients,16 we primarily focussed on
left ventricular function.
In a recent study echocardiography showed that
young Duchenne patients have regional myocardial
defects, not only systolic but also diastolic.17 Echo-
cardiography can be helpful to detect early dysfunction
in young Duchenne patients. Done properly, echo-
cardiography is viewed as the gold standard to evaluate
and quantify systolic and diastolic LV dysfunction.
Several studies show that echocardiography is reliable
and offers not only qualitative but also quantitative
information in Duchenne patients.10,17,18 However,
these studies have included mainly young, not
ventilator-dependent, patients. Our adult population
of ventilated DMD patients suffers from kyphoscoliosis
and obesity and is basically tetraparetic. They need a
patient lift to be positioned on an investigation table.
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Figure 2. Left ventricular ejection fraction (%) measured by multi-
gated cardiac radionuclide ventriculography (MUGA) versus left
ventricular function (LVF) measured by echocardiography and
NT-proBNP
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Even then examination is severely hampered by poor
acoustic windows. Echocardiography is generally
performed in this patient group in a wheelchair which
is not ideal but possible and practical. The duration of
the examination is about 15 minutes. 
MUGA scanning has been used to accurately assess
left ventricular ejection fraction in all types of patients.
Although it is an effective and sensitive technique for
assessing LV function in DMD,7 it is much more time
consuming. In total, this examination takes at least an
hour as the patient has to be positioned in front of the
camera and it is more laborious for the technician and
accompanying parents or other helpers, as well as more
burdensome for these severely disabled patients.
More advanced techniques, also currently used for
determining cardiac function in DMD patients such
as single photon emission computed tomography
(SPECT) analysis and cardiac magnetic resonance
(CMR), meet the same and perhaps even larger
problems concerning burden, labour and time. Never-
theless there are interesting studies showing the ability
to identify early fibrosis which seems to correlate with
LV dysfunction.3,4 These are promising and suitable
techniques for young and more mobile Duchenne boys
as well as for female carriers. 
In this study we did not focus on this last patient
group of female carriers of DMD, although they are
more frequently encountered and also at risk for cardiac
disease. In a study among adult carriers echocar-
diographic examination was abnormal in 38% of the
patients, including several patients with dilating
cardiomyopathy.19 We can imagine that NT-proBNP
is also useful in this patient group. In the literature
there is some evidence by Adachi et al. that carriers
had elevated brain natriuretic peptide, which correlated
with indices of cardiac function.20
Further longitudinal follow-up studies are needed
to determine whether early detection of subclinical
cardiac dysfunction changes cardiac prognosis and
whether early pharmaceutical interventions are useful
in preventing progression of Duchenne muscular
dystrophy. 
Although limited data are available, growing
evidence suggests that ACE inhibitors may prevent
onset and progression of LV failure and that β-blockers
may be cardioprotective in DMD.14,21,22 This carries
important implications and implies that extensive
routine cardiac assessment in addition to clinical
evaluation is essential. 
Conclusion
Important advances have improved our understanding
of the nature of disease and life expectancy in DMD
patients. Respiratory insufficiency is easily assessed and
accurately treated with chronic mechanical ventilatory
support. Despite these advantages, DMD continues
to be associated with considerable morbidity and
mortality, now often ascribed to the development of
cardiomyopathy. We show that the combination of
echocardiography and NT-proBNP achieves similar
results to MUGA scanning in the evaluation of left
ventricular function. This combination is less time
consuming and burdensome for our patients. We
advise adding NT-proBNP to echocardiography in the
routine cardiac assessment of DMD patients. In case
of normal echocardiographic findings (even if data
quality is limited) in combination with non-elevated
NT-proBNP, significant cardiomyopathy is rather un-
likely. Further research is needed to determine whether
tailoring medical therapy to NT-proBNP levels will
allow early institution of appropriate therapies and
improve outcome. ■
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